1448347-97-4Relevant academic research and scientific papers
HETEROARYL COMPOUNDS AS KINASE INHIBITOR
-
Page/Page column 87-88, (2019/10/04)
Provided herein are heteroaryl compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R 1, R 2, R 3, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof.
THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF
-
Page/Page column 70, (2015/02/19)
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column 69-70, (2015/02/19)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column, (2015/02/19)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column 69; 70, (2013/07/31)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
-
Page/Page column, (2013/07/31)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
